CAMBRIDGE, Mass. - Moderna’s COVID-19 vaccine generated a "robust" neutralizing antibody response in children ages 6 to 11, the company said Monday in a statement.
Moderna said it plans to seek authorization from the U.S. Food and Drug Administration for the age group soon.The company shared interim data from its Phase 2/3 study, which showed that two smaller doses of its COVID-19 vaccine given 28 days apart were generally well-tolerated in more than 4,750 children.